在患有慢性心力衰竭的患者中,尿道N终端前激素脑内尿性分泌
Gerard C M Linssen1, Kevin Damman, Hans L Hillege
1Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Circulation
|June 24, 2009
概括
在心力衰竭患者中,尿道N端前激素脑尿性 (NT-proBNP) 的分泌量减少,与血NT-proBNP水平相反相关. 这种与脏血流量相关的分泌量下降可能解释了心力衰竭中NT-proBNP的升高.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種神經病學.
- 生物标志物研究 生物标志物研究
背景情况:
- 尿液分泌是N终端前激素大脑尿性 (NT-proBNP) 的主要排泄途径.
- 在心力衰竭 (HF) 患者中测量尿路NT-proBNP的临床意义尚不清楚.
研究的目的:
- 为了研究慢性心力衰竭 (CHF) 患者的尿路NT-proBNP分泌.
- 确定尿路NT-proBNP,血NT-proBNP和CHF患者的功能之间的关系.
主要方法:
- 研究了94名心血管衰竭患者和20名健康对照.
- 使用放射性同位素清除,测量了膜过率和有效的脏血流量.
- 量化的血和24小时尿液NT-proBNP水平.
主要成果:
- 与对照组相比,CHF患者的尿路NT-proBNP分泌量显著降低.
- 尿中NT-proBNP分泌与血NT-proBNP水平有很强的反相关性.
- 降低脏血流量,但不是膜过率,与较低的尿路NT-proBNP分泌有关.
结论:
- 尿中NT-proBNP的分泌在CHF下降,与血NT-proBNP相反.
- 脏血流影响尿道NT-proBNP的分泌,独立于膜过率.
- 尿排泄减少可能导致心力衰竭患者血NT-proBNP升高.
相关概念视频
Neurotransmitters
Neurotransmitters play a crucial role in the communication between neurons in the autonomic nervous system. Neurons in the autonomic nervous system can be cholinergic or adrenergic depending on the neurotransmitters synthesized. Cholinergic neurons use acetylcholine as their primary neurotransmitter. This includes all the preganglionic fibers of the sympathetic and pre- and postganglionic fibers of the parasympathetic nervous systems. In addition, neurons of the somatic nervous system also use...
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...


